<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.0 20040830//EN" "http://dtd.nlm.nih.gov/publishing/2.0/journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" dtd-version="2.0" xml:lang="EN">
  <front>    <journal-meta>
      <journal-title>Journal of Clinical Medicine and Research</journal-title>
      <issn pub-type="epub">2141-2235</issn>      <publisher>
        <publisher-name>Academic Journals</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.5897/JCMR2014.0253</article-id>
      <title-group>
        <article-title><![CDATA[Treatment of recurrent refractory mantle cell lymphoma by thalidomide in combination with interferon]]></article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" xlink:type="simple">
        		        	<name name-style="western">
	            <surname>Lijie</surname>
            <given-names>Han</given-names>
	          </name>	
        		        	<name name-style="western">
	            <surname>Huifang</surname>
            <given-names>Zhao</given-names>
	          </name>	
        		        	<name name-style="western">
	            <surname>Qingsong</surname>
            <given-names>Yin</given-names>
	          </name>	
        		        	<name name-style="western">
	            <surname>Lin</surname>
            <given-names>Chen</given-names>
	          </name>	
        		        	<name name-style="western">
	            <surname>Yongping</surname>
            <given-names>Song</given-names>
	          </name>	
        		        	<name name-style="western">
	            <surname>Xudong</surname>
            <given-names>Wei</given-names>
	          </name>	
        	        </contrib>
      </contrib-group>
      <author-notes>
		<corresp id="cor1">* E-mail: <email xlink:type="simple">xudongwei@zzu.edu.cn</email></corresp>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="epub">
      	<day>30</day>
        <month>04</month>
        <year>2015</year>
      </pub-date>
      <history>
      			<date date-type="received">
			<day>08</day>
			<month>07</month>
			<year>2014</year>
		</date>
						<date date-type="accepted">
			<day>17</day>
			<month>04</month>
			<year>2015</year>
		</date>
			  </history>
      <volume>7</volume>
      <issue>2</issue>
	  	  <fpage>7</fpage>
	  <lpage>10</lpage>
      <permissions>
		<license xlink:type="simple">
			<license-p>
			This is an open-access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
			</license-p>
		</license>
	  </permissions>
	  <self-uri xlink:href="http://politicalwaffle.uk/journal/JCMR/article-abstract/AA29A7453113">
		This article is available from http://politicalwaffle.uk/journal/JCMR/article-abstract/AA29A7453113	  </self-uri>
	  <self-uri xlink:href="http://politicalwaffle.uk/journal/JCMR/article-full-text-pdf/AA29A7453113">
		The full text article is available as a PDF file from http://politicalwaffle.uk/journal/JCMR/article-full-text-pdf/AA29A7453113	  </self-uri>
	  
      <abstract><![CDATA[Mantle cell lymphoma (MCL) is a highly aggressive non-Hodgkin#39;s lymphoma with poor prognosis. This study aims to explore a new, safe approach for patients with recurrent refractory MCL. A total of six patients with recurrent refractory MCL were recruited. They all accepted thalidomide tablets (100 mg/day) orally every night, accompanied with interferon alpha;-2b (3 million units, injected subcutaneously) every other day. The patients were followed up for 41, 25, 20, 30, 40 and 36 months, respectively, with a median follow-up time of 33 months (20 to 41 months). No severe adverse reactions occurred. For patients with recurrent refractory MCL, the combination of thalidomide and interferon alpha;-2b showed a positive result to provide them a longer survival period with higher quality of life.

	 

	Key words: Recurrent refractory mantle cell lymphoma, thalidomide, interferon alpha;-2b, combination, adverse reaction.]]></abstract>
    </article-meta>
  </front>
      <body/>
    <back>
		<ref-list>
			<title>References</title>
						<ref id="ref1">
				<label>1</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Armitage JO, Coiffier B (2000). Activity of interferon- in relapsed patients with diffuse large B-cell and peripheral T-cell non-Hodgkins lymphoma. Ann. Oncol. 11(3)359-361.
				]]>
				</mixed-citation>
			</ref>
						<ref id="ref2">
				<label>2</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[DAmato RJ, Loughran MS, Flynn E, Folkman J (1994). Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA. 91:4082-4085.
				]]>
				</mixed-citation>
			</ref>
						<ref id="ref3">
				<label>3</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Damaj G, Lefrere F, Delarue R, Varet B, Furman R, Hermine O (2003). Thalidomide therapy induces response in relapsed mantle cell lymphoma. Leukemia 17(9):1914-1915.
				]]>
				</mixed-citation>
			</ref>
						<ref id="ref4">
				<label>4</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, Lin B, Podar K, Gupta D, Chauhan D, Treon SP, Richardson PG, Schlossman RL, Morgan GJ, Muller GW, Stirling DI, Anderson KC (2001). Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98(1):210-216.
				]]>
				</mixed-citation>
			</ref>
						<ref id="ref5">
				<label>5</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Davis TA, Maloney DG, Grillo AJ (2000). Combination immunotherapy of relapsed or refractory lowgrade or follicular non-Hodgkins lymphoma with rituximab and interferon-2a. Clin. Cancer Res. 6:2644-2652.
				]]>
				</mixed-citation>
			</ref>
						<ref id="ref6">
				<label>6</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Haslett PAJ, Corral LG, Albert M, Kaplan G (1998). Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J. Exp. Med. 187(11)1885-1892.
				]]>
				</mixed-citation>
			</ref>
						<ref id="ref7">
				<label>7</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Kaufmann H, Raderer M, Whrer S, Pspk A, Bankier A, Zielinski C, Chott A, Drach J (2004). Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle eell lymphoma. Blood 104(8):2269-2271.
				]]>
				</mixed-citation>
			</ref>
						<ref id="ref8">
				<label>8</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Richardson P, Hidershima T, Anderson K (2002). Thalidomide: Emerging role in cancer medicine. Ann. Rev. Med. 53:629-657.
				]]>
				</mixed-citation>
			</ref>
						<ref id="ref9">
				<label>9</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Sacchi S, Federico M, Vitolo U, Boccomini C, Vallisa D, Baldini L, Petrini M, Rupoli S, Di Raimondo F, Merli F, Liso V, Tabilio A, Saglio G, Vinci G, Brugiatelli M, Dastoli G (2001). Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non-Hodgkins lymphoma. Haematologica 86(9):951-958.
				]]>
				</mixed-citation>
			</ref>
						<ref id="ref10">
				<label>10</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Wilson EA, Jobanputra S, Jackson R, Parker AN, McQuaker IG (2002). Response to thalidomide in chemotherapy-resistant mantle cell lymphoma:a case report.Br. J. HaematoI. 119(1)128-130.
				]]>
				</mixed-citation>
			</ref>
					</ref-list>
	</back>
    </article>